| Drug Name | ULTOMIRIS® (ravulizumab) |
|---|---|
| Drug Class | |
| Risk minimization type |
Patient Card
Healthcare provider guide
patient guide
Other
|
| Specialty (Theraputic area) | |
| Risk |
- To inform the patients and healthcare providers about the risk of meningococcal infection associated with ravulizumab. - To educate patients, parents/ legal guardians of infants and children and healthcare providers about the safety considerations associated with ravulizumab treatment. |
| Patient card |
|
| patient guide |
|
| Health care provider guide |
|
| other |
|